People · Operator
Named in public records as an officer, director or promoter · active 2014–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MyoKardia Inc | — | Biotechnology | Series C | $60.0M | $1.9B | 2014 |
Tassos Anastasios Gianakakos at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tassos Anastasios Gianakakos on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Perry | 1 | 6 |
| Kevin Starr | 1 | 5 |
| Charles Homcy | 1 | 4 |
| Katherine Bowdish | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.